[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA41097A - ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORAL PROPERTIES AND DERIVATIVES OF SAID ANTIBODIES FOR USE TO TREAT BONE PAIN - Google Patents

ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORAL PROPERTIES AND DERIVATIVES OF SAID ANTIBODIES FOR USE TO TREAT BONE PAIN

Info

Publication number
MA41097A
MA41097A MA041097A MA41097A MA41097A MA 41097 A MA41097 A MA 41097A MA 041097 A MA041097 A MA 041097A MA 41097 A MA41097 A MA 41097A MA 41097 A MA41097 A MA 41097A
Authority
MA
Morocco
Prior art keywords
antibodies
inhibitoral
derivatives
enhanced
properties
Prior art date
Application number
MA041097A
Other languages
French (fr)
Inventor
Sachin Kumar Dubey
Adrian Walmsley
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/562,297 external-priority patent/US20150183885A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MA41097A publication Critical patent/MA41097A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA041097A 2014-12-05 2015-12-06 ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORAL PROPERTIES AND DERIVATIVES OF SAID ANTIBODIES FOR USE TO TREAT BONE PAIN MA41097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/562,297 US20150183885A1 (en) 2012-06-08 2014-12-05 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
EP15165107 2015-04-24

Publications (1)

Publication Number Publication Date
MA41097A true MA41097A (en) 2017-10-10

Family

ID=54838344

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041097A MA41097A (en) 2014-12-05 2015-12-06 ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORAL PROPERTIES AND DERIVATIVES OF SAID ANTIBODIES FOR USE TO TREAT BONE PAIN

Country Status (7)

Country Link
EP (1) EP3227334A1 (en)
JP (1) JP2018505853A (en)
CN (1) CN107207599A (en)
CA (1) CA2969940A1 (en)
HK (1) HK1244012A1 (en)
MA (1) MA41097A (en)
WO (1) WO2016087677A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541365A1 (en) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
JP7183268B2 (en) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド Aflibercept formulation containing lysine salt as tonicity agent and its use
AR114110A1 (en) * 2018-02-28 2020-07-22 Lilly Co Eli ANTI-TRKA ANTIBODY
CN112010978B (en) * 2019-05-30 2022-04-08 广东东阳光药业有限公司 Antibodies to TrkA and uses thereof
TW202210467A (en) 2020-05-28 2022-03-16 美商美國禮來大藥廠 Trka inhibitor
EP4457246A1 (en) * 2021-12-28 2024-11-06 4B Technologies (Suzhou) Limited Trka antibody and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (en) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20030601A1 (en) * 2003-12-24 2005-06-25 Lay Line Genomics Spa METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED.
NZ563392A (en) * 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
ITRM20050290A1 (en) * 2005-06-07 2006-12-08 Lay Line Genomics Spa USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS.
ITRM20050332A1 (en) * 2005-06-24 2006-12-25 Lay Line Genomics Spa USE OF MOLECULES ABLE TO BLOCK TRKA'S ACTIVITY TO STRENGTHEN THE EFFECTS OF ANALGESIC OPPIACEI ON PAIN.
PT2252633E (en) * 2008-02-04 2013-11-19 Lay Line Genomics Spa Anti-trka antibodies and derivatives thereof
US9783602B2 (en) * 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2013273115B2 (en) * 2012-06-08 2018-03-01 Ichnos Sciences SA Humanized anti-TrkA antibodies with amino acid substitutions

Also Published As

Publication number Publication date
HK1244012A1 (en) 2018-07-27
CA2969940A1 (en) 2016-06-09
EP3227334A1 (en) 2017-10-11
CN107207599A (en) 2017-09-26
WO2016087677A1 (en) 2016-06-09
JP2018505853A (en) 2018-03-01

Similar Documents

Publication Publication Date Title
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL304429A (en) Methods and compositions for treatment of epileptic disorders
HK1259075A1 (en) Bcma antibodies and use of same to treat cancer and immunological disorders
MA44146A (en) COMBINATION OF ANTI-PD-1 AND BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES TO TREAT CANCER
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
MA46481A (en) COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED METHODS
MA41028A (en) METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES
MA43135A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
MA41097A (en) ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORAL PROPERTIES AND DERIVATIVES OF SAID ANTIBODIES FOR USE TO TREAT BONE PAIN
IL252943A0 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
MA55629A (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
EA201691582A1 (en) NEW PHARMACEUTICAL PREPARATIONS
MA43378A (en) COMPOSITIONS AND METHODS FOR REDUCTION OF IMMUNE RESPONSE AGAINST CHEMERIC ANTIGEN RECEPTORS
HK1249016A1 (en) Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
IL254386A0 (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
MA43570A (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
GB201618424D0 (en) Treatment of antibody mediated disease
MA43230A (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BUBBLE EPIDERMOLYSIS
EP3534932C0 (en) Treatment of diseases related to igfb3 and its receptor
MA50532A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERS
MA40868A (en) PHARMACEUTICAL COMBINATIONS OF SITAGLIPTIN AND PPAR AGONISTS
FR3031902B1 (en) COMPOSITION OF SUPPLEMENTS AFTER MEDICAL INTERVENTION TO TREAT OBESITY
MA44978A (en) COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER
TH182641B (en) Composition and methods for the treatment of hemoglobin disorders